TNG Transgene SA

Availability of Transgene's 2023 Universal Registration Document

Availability of Transgene's 2023 Universal Registration Document

TRANSGENE (Paris: TNG) today announced that its Universal registration document for the fiscal year ended December 31, 2023, was submitted to the French stock market authority (Autorité des Marchés financiers – AMF) in ESEF format and registered under the reference D.24-0274.

The 2023 Universal Registration Document is available to the public under the conditions provided by applicable regulations. The document is available on the Company’s website: , in the “Investors/Financial information” section and on the AMF website: -france.org.

It includes:

  • the 2023 annual financial report;
  • the report of the Board of Directors on corporate governance;
  • the statutory auditor’s reports;
  • information on the share buyback program;
  • information related on the auditor’s fees.

The universal registration document also includes information on the Company’s environmental and social responsibility.

Contacts

Transgene:

Lucie Larguier

Chief Financial Officer

+33 (0)3 88 27 91 04

 

Attachment



EN
11/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Transgene SA

 PRESS RELEASE

Transgene Announces Financial Calendar for 2026

Transgene Announces Financial Calendar for 2026 Strasbourg, France, February 4, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG) a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its financial reporting and Annual shareholders’ meeting dates for 2026: March 24, 2026:               2025 Fiscal Year Results April 29, 2026:                 First Quarter 2026 Financial Results May 13, 2026:                   Annual Shareholders’ Meeting September 24, 2026:       First Half 2026 Financial Results  November 9, 2026:     ...

 PRESS RELEASE

Transgene présente son calendrier de communication financière pour 202...

Transgene présente son calendrier de communication financière pour 2026 Strasbourg (France), le 4 février 2026, 17 h 45 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies reposant sur des vecteurs viraux contre les cancers, annonce aujourd'hui son calendrier de communication financière pour 2026 et la date de son Assemblée générale annuelle : 24 mars 2026 :                   Résultats annuels de l’exercice 2025 29 avril 2026 :                    Résultats financiers du premier trimestre 2026 13 mai 2026 :                     Assembl...

 PRESS RELEASE

Transgene Further Strengthens Scientific Advisory Board with Appointme...

Transgene Further Strengthens Scientific Advisory Board with Appointments of Renowned Cancer Immunotherapy Experts Antoine Italiano and Ignacio Melero Strasbourg, France, January 23, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced the appointment of two additional key scientific advisors to its Scientific Advisory Board, Prof. Antoine Italiano, MD, PhD, and Prof. Ignacio Melero, MD, PhD, further strengthening its scientific leadership. “Antoine and Ignacio are world leaders...

 PRESS RELEASE

Transgene renforce son comité scientifique avec l’arrivée d’Antoine It...

Transgene renforce son comité scientifique avec l’arrivée d’Antoine Italiano et Ignacio Melero, deux experts renommés en immunothérapie du cancer Strasbourg, France, 23 janvier 2026, 8 h 00 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies reposant sur des vecteurs viraux contre les cancers, annonce la nomination de deux nouveaux experts au sein de son comité scientifique, le Prof Antoine Italiano, MD, PhD, et le Prof Ignacio Melero, MD, PhD, renforçant ainsi son leadership scientifique. « Reconnus internationalement pour leur leader...

Thibaut Voglimacci-Stephanopoli
  • Thibaut Voglimacci-Stephanopoli

ResearchPool Subscriptions

Get the most out of your insights

Get in touch